Xospata (fliterenib) – pro
XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test this patient is in remission post STEM CELL Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase III ADMIRAL trial. American Association of Cancer Research (AACR) Annual Meeting, April 2, 2019. Abstr CT184. Available at: https://www.abstractsonline.com/pp8/#!/6812/presentation/9835. Accessed July 29, 2019. However, indefinite use as maintenance has not been studied
Although the use of FLT3 inhibitors in the pre-HSCT perspective is more clearly defined, its use in the post-HSCT scenario, when most relapses occur, remains unclear. (Grace Xiuqing Li et al).
Maintenance
XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test this patient is in remission post STEM CELL Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase III ADMIRAL trial. American Association of Cancer Research (AACR) Annual Meeting, April 2, 2019. Abstr CT184. Available at: https://www.abstractsonline.com/pp8/#!/6812/presentation/9835. Accessed July 29, 2019. However, indefinite use as maintenance has not been studied
Although the use of FLT3 inhibitors in the pre-HSCT perspective is more clearly defined, its use in the post-HSCT scenario, when most relapses occur, remains unclear. (Grace Xiuqing Li et al).
Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase III ADMIRAL trial. American Association of Cancer Research (AACR) Annual Meeting, April 2, 2019. Abstr CT184. Available at: https://www.abstractsonline.com/pp8/#!/6812/presentation/9835. Accessed July 29, 2019.
XOSPATA (gilteritinib) [prescribing information]. Northbrook, IL: Astellas Pharma US; 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf. Accessed July 29, 2019.
OSPATA (gilteritinib) [prescribing information]. Northbrook, IL: Astellas Pharma US; 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf. Accessed July 29, 2019.
Weis TM, Marini BL, Bixby DL, Perissinotti AJ. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2019;141:125-38.
Li GX, Wang L, Yaghmour B, Ramsingh G, Yaghmour G. The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant. Leuk Res Rep. 2018 Jul 19;10:26-36.
Weis TM, Marini BL, Bixby DL, Perissinotti AJ. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2019;141:125-38.